Jordi Madariaga Burgos, Estefanía Vega, María Luisa García, Montserrat Pujol, Elena Sánchez-López, Eliana B Souto
{"title":"Biodegradable nanoplatforms for antigen delivery: part II - nanoparticles, hydrogels, and microneedles for cancer immunotherapy.","authors":"Jordi Madariaga Burgos, Estefanía Vega, María Luisa García, Montserrat Pujol, Elena Sánchez-López, Eliana B Souto","doi":"10.1080/17425247.2024.2400291","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, chimeric antigen receptor T (CAR-T) cell therapy has resulted in a breakthrough in the treatment of patients with refractory or relapsed hematological malignancies. However, the identification of patients suitable for CAR-T cell therapy needs to be improved.</p><p><strong>Areascovered: </strong>CAR-T cell therapy has demonstrated excellent efficacy in hematological malignancies; however, views on determining when to apply CAR-T cells in terms of the evaluation of patient characteristics remain controversial.</p><p><strong>Expert opinion: </strong>We reviewed the current feasibility and challenges of CAR-T cell therapy in the most common hematological malignancies and classified them according to disease type and treatment priority, to guide clinicians and researchers in applying and investigating CAR-T cells further.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2024.2400291","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: In recent years, chimeric antigen receptor T (CAR-T) cell therapy has resulted in a breakthrough in the treatment of patients with refractory or relapsed hematological malignancies. However, the identification of patients suitable for CAR-T cell therapy needs to be improved.
Areascovered: CAR-T cell therapy has demonstrated excellent efficacy in hematological malignancies; however, views on determining when to apply CAR-T cells in terms of the evaluation of patient characteristics remain controversial.
Expert opinion: We reviewed the current feasibility and challenges of CAR-T cell therapy in the most common hematological malignancies and classified them according to disease type and treatment priority, to guide clinicians and researchers in applying and investigating CAR-T cells further.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
